Company Overview and News

4
SND / Smart Sand, Inc. 8-K (Current Report)

2018-04-12 sec.gov
snd-8k_20180406.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Upvote Downvote

 
SND / Smart Sand, Inc. null

2018-04-02 sec.gov
begin 644 filename1.pdf M)5!$1BTQ+C4-)>+CS],-"C$P(# @;V)J#3P\+TQI;F5A#0IE;F1S M=')E86T-96YD;V)J#7-T87)T>')E9@T*, T*)25%3T8-"B @(" @(" @#0HR M,B P(&]B:@T\/"]&:6QT97(O1FQA=&5$96-O9&4O22 X-"],(#8X+TQE;F=T M:" V,2]3(#,X/CYS=')E86T-"FC>8F!@8&9@
Upvote Downvote

 
Just The Numbers... Plus: Frac Sand Companies

2018-03-29 seekingalpha
Frac sand entities take several forms: as divisions of large oilfield service companies, as part of public industrial sand companies or limited partnerships, and as private companies.
Upvote Downvote

 
BRIEF-Smart Sand Announces New Multi-Year Take-Or-Pay Contract

2018-03-20 reuters
* SMART SAND INC - ENTERED INTO A MULTI-YEAR MASTER PRODUCT PURCHASE AGREEMENT WITH A LARGE EXPLORATION AND PRODUCTION COMPANY Source text for Eikon: Further company coverage:
Upvote Downvote

 
Smart Sand, Inc. Announces New Multi-Year Take-or-Pay Contract

2018-03-20 globenewswire
THE WOODLANDS, Texas, March 20, 2018 (GLOBE NEWSWIRE) -- Smart Sand, Inc. (NASDAQ:SND) announced today that, in anticipation of its recent acquisition of the rights to a unit train capable transloading terminal in Van Hook, North Dakota, it entered into a multi-year Master Product Purchase Agreement (the “Agreement”) with a large exploration and production company. The products will be sold through the newly acquired transloading terminal, and the obligations under the Agreement will commence after such facility is operational, which we expect will be in April 2018.
Upvote Downvote

2
Smart Sand Shares Hammered: Justified Sell-Off Or March Madness?

2018-03-20 seekingalpha
Despite such strong performance, a run-up in expenses and indication that the company will access its revolving credit facility seem to be behind a 15% post-earnings sell-off.
Upvote Downvote

 
Smart Sand, Inc. Announces New Bakken Frac Sand Transloading Terminal

2018-03-16 globenewswire
THE WOODLANDS, Texas, March 16, 2018 (GLOBE NEWSWIRE) -- Smart Sand, Inc. (NASDAQ:SND) (the “Company”) announced today that it acquired the rights to operate a unit train capable transloading terminal in Van Hook, North Dakota to service the Bakken Formation. The Company paid consideration of approximately $15.5 million to acquire certain assets at the Van Hook terminal, and has entered into a long-term lease agreement in connection with the transaction.
Upvote Downvote

 
BRIEF-Press Release - Smart Sand, Inc. Announces New Bakken Frac Sand Transloading Terminal

2018-03-16 reuters
* SMART SAND INC - PAID CONSIDERATION OF APPROXIMATELY $15.5 MILLION TO ACQUIRE CERTAIN ASSETS AT VAN HOOK TERMINAL
Upvote Downvote

 
Smart Sand's (SND) CEO Charles Young on Q4 2017 Results - Earnings Call Transcript

2018-03-15 seekingalpha
Good day, ladies and gentlemen and welcome to the Smart Sand Fourth Quarter and Full Year 2017 Earnings Conference Call. [Operator Instructions]. As a reminder this conference is being recorded. I would now like to hand the floor over to Phil Cerniglia, Investor Relations Manager. Please go ahead, sir.
Upvote Downvote

1
SND / Smart Sand, Inc. 8-K (Current Report)

2018-03-15 sec.gov
snd-8k_20180315.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Upvote Downvote

1
SND / Smart Sand, Inc. 10-K (Annual Report)

2018-03-15 sec.gov
snd-10k_20171231.htm
Upvote Downvote

1
5 of the Best Stocks Under $10 for 2018

2018-03-05 zacks
Here at Zacks, we don’t generally classify stocks as “cheap” or “expensive,” and rather than looking at the stock’s face value, we have a system that puts an emphasis on earnings estimate revisions to find stocks that will hopefully be winners for investors.
Upvote Downvote

 
SND / Smart Sand, Inc. / Clearbridge Investments, LLC - NONE (Passive Investment)

2018-02-16 sec.gov
Schedule 13G   UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549   SCHEDULE 13G     Under the Securities Exchange Act of 1934 (Amendment No. n/a )*   Smart Sand, Inc.  (Name of Issuer)   Common Stock (Title of Class of Securities)   83191H107 (CUSIP Number)   December 31, 2017 (Date of Event Which Requires Filing of this Statement)   Check the appropriate box to designate the rule pursuant to which this Schedule is filed:        x  Rule 13d-1(b)        o  Rule 13d-1(c)     
Upvote Downvote

 
SND / Smart Sand, Inc. / Clearbridge Investments, LLC - NONE (Passive Investment)

2018-02-15 sec.gov
Schedule 13G   UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549   SCHEDULE 13G     Under the Securities Exchange Act of 1934 (Amendment No. n/a )*   Smart Sand, Inc.  (Name of Issuer)   Common Stock (Title of Class of Securities)   83191H107 (CUSIP Number)   December 31, 2017 (Date of Event Which Requires Filing of this Statement)   Check the appropriate box to designate the rule pursuant to which this Schedule is filed:        x  Rule 13d-1(b)        o  Rule 13d-1(c)     
Upvote Downvote

Related Articles

RDHL: Redhill Biopharma Ltd (OTC:REDIF) Analysis and Research Report

2018-04-18 - Asif

History and Development of the Company The company's legal and commercial name is RedHill Biopharma Ltd. The company's company was incorporated on August 3, 2009, and was registered as a private company limited by shares under the laws of the State of Israel. The company's principal executive offices are located at 21 Ha’arba’a Street, Tel Aviv, Israel. In February 2011, the company completed its initial public offering in Israel, pursuant to which the company issued 14,302,300 Ordinary Shares, and 7,151,150 tradable Series 1 Warrants to purchase 7,151,150 Ordinary Shares for aggregate gross proceeds of approximately $14 million. On December 27, 2012, the company completed the listing of its ADSs on the NASDAQ Capital Market. The company's Ordinary Shares are traded on the Tel-Aviv Stock Exchange under the symbol “RDHL,” and its ADSs are traded on the NASDAQ Capital Market under the same symbol "RDHL". The company's capital expenditures for the years ended December 31, 2...

SCYX: SCYNEXIS Analysis and Research Report

2018-04-16 - Asif

Overview SCYNEXIS, Inc. is a biotechnology company committed to positively impacting the lives of patients suffering from difficult-to-treat and often life-threatening infections by delivering innovative anti-infective therapies. SCYNEXIS is developing its lead product candidate, SCY-078, as the first representative of a novel oral and intravenous (IV) triterpenoid antifungal family in clinical development for the treatment of several serious fungal infections, including invasive candidiasis, invasive aspergillosis, refractory invasive fungal infections and vulvovaginal candidiasis (VVC). SCY-078 is a structurally distinct glucan synthase inhibitor that has been shown to be effective in vitro and in vivo against a broad range of human fungi pathogens such as Candida and Aspergillus species, including multidrug-resistant strains, as well as Pneumocystis species. Candida and Aspergillus species are the fungi responsible for approximately 85% of all invasive fungal infections in t...

ENRT: Enertopia Corp (CNSX:TOP) Analysis and Research Report

2018-04-16 - Asif

Business History Enertopia Corp. was formed on November 24, 2004 under the laws of the State of Nevada and commenced operations on November 24, 2004. From inception until April 2010, the company were primarily engaged in the acquisition and exploration of natural resource properties. Beginning in April 2010, the company began its entry into the renewable energy sector by purchasing an interest in a solar thermal design and installation company. In late summer 2013, the company began its entry into medicinal marijuana business. During its 2014 fiscal year end its activities in the clean energy sector were discontinued. During fiscal 2015 its activities in the Medicinal Marijuana sector were discontinued. During fiscal 2016 its activities in the Women’s personal healthcare sector were discontinued. The Company is actively pursuing business opportunities in the resource sector, whereby the company signed a definitive agreement for a Lithium Brine Project in May 2016. In May ...

FB: Facebook Analysis and Research Report

2018-04-15 - Asif

Overview The company's mission is to give people the power to build community and bring the world closer together. The company's top priority is to build useful and engaging products that enable people to connect and share with friends and family through mobile devices, personal computers, and other surfaces. The company also help people discover and learn about what is going on in the world around them, enable people to share their opinions, ideas, photos and videos, and other activities with audiences ranging from their closest friends to the public at large, and stay connected everywhere by accessing its products, including: Facebook enables people to connect, share, discover, and communicate with each other on mobile devices and personal computers. There are a number of different ways to engage with people on Facebook, the most important of which is News Feed which displays an algorithmically-ranked series of stories and advertisements individualized for each pers...

VSTM: Verastem Analysis and Research Report

2018-04-12 - Asif

Business Overview Verastem is a biopharmaceutical company focused on developing and commercializing drugs to improve the survival and quality of life of cancer patients. The company's most advanced product candidates, duvelisib and defactinib, utilize a multi-faceted approach to treat cancers originating either in the blood or major organ systems. Verastem is currently evaluating these compounds in both preclinical and clinical studies as potential therapies for certain cancers, including leukemia, lymphoma, lung cancer, ovarian cancer, mesothelioma, and pancreatic cancer. The company believe that these compounds may be beneficial as therapeutics either as single agents or when used in combination with immuno-oncology agents or other current and emerging standard of care treatments in aggressive cancers that are poorly served by currently available therapies. Duvelisib targets the Phosphoinositide 3-kinase (PI3K) signaling pathway. The PI3K signaling pathway plays a centr...

CUSIP: 83191H107